The conversation discusses the potential of topical cetirizine (Zyrtec) for hair growth in comparison to minoxidil, noting cetirizine's ability to reduce prostaglandin D2, which inhibits hair growth. Users share mixed experiences with cetirizine for allergies and scalp health, and there's a mention of the risk of dementia with long-term antihistamine use.
Switching from topical to oral minoxidil due to scalp irritation and unsatisfactory results, while also seeking cheaper options in the U.S. Oral minoxidil is generally favored for its effectiveness and fewer application downsides, with CostPlusDrugs and GoodRx offering affordable prices.
The conversation discusses using ZIX, a combination of Zinc Sulfate and Vitamin B6, for hair loss. The user is considering liquid forms for better absorption and scalp health.
The conversation discusses disappointment over only receiving a financial report from Cassiopea instead of trial results for Breezula/CB-03-01, a hair loss treatment. However, there is optimism as the company is advancing Breezula into Phase III trials for men, starting trials for women, and submitting an NDA for their acne product, Winlevi.
A 42-year-old is using a topical solution with 5% minoxidil and 0.1% finasteride, along with weekly microneedling, for hair regrowth without side effects. The product used is Tugain for men by Cipla, an Indian brand.
Veradermics' new hair loss treatment, VDPHL01, is likely a modified release oral minoxidil, which has received $75 million in funding for clinical trials. Despite skepticism about investing in a known treatment, some believe it could offer improved efficacy and reduced side effects.
RU58841 should be stored in the refrigerator to maintain efficacy, but it remains stable for over two years even without refrigeration. A user prefers using Minoxidil and finasteride instead.
Hair loss treatments discussed include Minoxidil, Finasteride, and Spironolactone. One user shares success with Finasteride, Minoxidil, and low-dose Cyproterone Acetate, but warns against long-term use of oral anti-androgens.
The user is experiencing white flakes and a greasy look from using a topical solution containing 0.025% finasteride, 8% minoxidil, 0.01% retinoic acid, and 1% hydrocortisone. Suggestions include reducing application frequency, using a brush to clean the scalp, and considering alcohol-free alternatives.
Bimatoprost is discussed for hair and eyelash growth, with users confirming its legitimacy and availability from Indian pharmacies. It is noted that the common concentration may not be effective for significant scalp hair regrowth unless mixed with Minoxidil.
The conversation is about whether stemoxydine can shorten the dormant phase after a hair transplant, known as the ugly duckling phase. There is skepticism about whether it actually works as claimed.
The user experiences severe headaches from 5% minoxidil and is considering mixing finasteride with a 2% minoxidil solution or diluting a 5% minoxidil + 0.1% finasteride solution. They seek advice on the appropriate method and dilutant composition.
A user inquired about Cipla Tugain Men, a topical solution containing Minoxidil 5% and Finasteride 0.1%, noting its less greasy texture and good price. Responses suggest it's similar to other products with the same ingredients, questioning the effectiveness of additional components.
Redensyl is being discussed as a potential substitute for minoxidil for hair growth after a brand switched from minoxidil to redensyl. The user is inquiring about the effectiveness of redensyl compared to minoxidil.
RU58841 lacks FDA approval due to financial and safety concerns, including potential cardiological side effects. The company abandoned further research, and users report adverse effects like heart palpitations and gynecomastia.
A quercetin-encapsulated and polydopamine-integrated nanosystem (PDA@QLipo) shows promise for treating androgenetic alopecia by reshaping the perifollicular microenvironment, outperforming minoxidil in hair regeneration. The nanosystem promotes cell proliferation, hair follicle renewal, and recovery by scavenging reactive oxygen species and enhancing neovascularity.
A user is experiencing scalp flaking from a finasteride/minoxidil topical solution and considers using salicylic acid shampoo to remove propylene glycol residue. Another user suggests trying a leave-in conditioner to address dryness and flaking.
A 29-year-old male is using alcohol-based 5% topical minoxidil, oral minoxidil 2.5 mg daily, and dermarolling to address hair loss, after discontinuing topical finasteride due to sexual side effects. He notices improved hair quality and thickness but is concerned about density and seeks feedback on his progress.
Stem cell and exosome injections for hair loss are discussed, with skepticism about their effectiveness and concerns about using non-genetically related stem cells. Dr. Deyarmin's treatments are mentioned, with some users questioning their legitimacy and others expressing curiosity.
The conversation discusses using very low dose topical finasteride to achieve specific serum DHT reduction percentages. It concludes that finasteride dosage increases linearly between 5-30% DHT reduction but requires exponential increases for reductions up to 70%.
The conversation humorously suggests using immunosuppressants like ciclosporine and oral minoxidil for hair regrowth, with a satirical plan involving hair transplants from family members. It highlights the side effects and impracticality of such treatments, emphasizing the post's satirical nature.
Creatine does not increase DHT levels or cause hair loss. Personal experiences vary, but scientific evidence shows no link between creatine and hair loss.
Minoxidil and spironolactone are used for hair regrowth, with visible progress noted. Spironolactone is discussed as a treatment option, particularly in the context of transitioning, with concerns about its effects on men.
The conversation is about using Tretinoin with Minoxidil for hair loss treatment, discussing the effectiveness and personal experiences with different concentrations. The image linked in the post received negative reactions for being unpleasant.
HMI-115 is a new drug developed by Bioinvent and licensed by Bayer, with mixed opinions on its potential effectiveness. Some users are skeptical and prefer proven treatments like Minoxidil, finasteride, and RU58841.
The conversation discusses GT20029, a drug in Phase II trials that targets androgen receptors with minimal systemic effects, and TDM-105795, a growth stimulant with a different mechanism than minoxidil that may revive papilla stem cells. Both are potential new treatments for hair loss.